AVIR

3.9600.76%
JM

Janet M. J. Hammond

Chief Development Officer

Dr. Janet M. J. Hammond, M.D., Ph.D., is Non-Executive Director of Enterprise Therapeutics Ltd. since May 2024. Dr. Janet M. J. Hammond serves as Member of Scientific Advisory Board at QILU Regor Therapeutics Inc. Dr. Hammond has been the Chief Development Officer at Atea Pharmaceuticals, Inc. since August 2020. Dr. Hammond is an Attending Physician at the West Los Angeles Veterans Administration Hospital. Dr. Hammond has extensive knowledge in the areas of virology and infectious diseases, sound clinical expertise as well as ample regulatory experience. She served as Vice President and Therapeutic Area Head for General Medicine and Infectious Disease Development at AbbVie, Inc. from November 2016 to August 2020. She served as Senior Vice President, Global Head of Infectious Diseases and Head of Pharmaceutical Research and Early Development China at F. Hoffmann-La Roche from March 2011 to November 2016, managing early clinical development strategy and implementation. Dr. Hammond served as Vice President of Translational Medicine for virology in pharmaceutical research and early development at Qforma Inc. Dr. Hammond began her career as a Clinical Program Head of Clinical Discovery in Virology at GlaxoSmithKline (GSK), where she oversaw founding and development of a new department and its medical strategy, IND submissions and clinical development of small molecules and vaccines. Subsequently she led the Early Clinical research team at Bristol-Myers Squibb responsible for HIV Early Development and Virology Life Cycle management. Dr. Hammond served as Vice President of Translational Medicine at Roche Holding AG since March 28, 2011. Dr. Hammond has made numerous contributions to the field. These include: three New Drug Applications (NDA) and Marketing Authorization Application (MAA) submissions, more than 10 supplemental NDAs and project lead in translational medicine on more than 10 Investigational New Drug (IND) submissions. In addition, Dr. Hammond was involved in launch preparations for three new drugs and managed the integration and development of new departments as a result of major company acquisitions. Prior to Roche, she served as Chief Medical Officer and Senior Vice President of Global Medical Affairs at Valeant Pharmaceuticals International, where she was responsible for medical affairs and pharmacovigilence activities worldwide. As Chair of the Global Safety Board at Valeant, Dr. Hammond was also responsible for ensuring patient, clinical trial and product safety. She also held other industry positions including Group Director, Global Clinical Research, Virology and Infections Diseases at Bristol-Myers Squibb, where she served as Medical Lead for the Early Clinical research team for HIV Early Development and Virology Life Cycle management; and at GlaxoSmithKline, she served as Head of Clinical Drug Discovery Virology, responsible for developing a new department as well as medical strategy, IND submissions and clinical development of small molecules and vaccines. She is a Reviewer for Lancet and the European Journal of Medical Microbiology. She has been a Member of Scientific Advisory Board at Viriom Inc. since October 2016. Dr. Hammond is a Member of the College of Medicine of South Africa, International Society of Infectious Diseases, Infectious Diseases Society of America and Southern African Critical Care Society. She is an Adjunct Faculty Member at UCLA. She has authored more than 45 publications and is a sought after Presenter at scientific meetings. In addition, she has received numerous awards and honors during her career. Dr. Hammond received her MD and PhD degrees from the University of Cape Town, South Africa and her Sc.M. in Clinical Investigation from Johns Hopkins University School of Hygiene and Public Health. She is a Fellow of the South African College of Physicians in Internal Medicine. She trained as a Clinical Fellow in the Division of Infectious Diseases at Duke University and as a Post Doctoral Clinical and Research Fellow in the Divisions of Clinical Pharmacology and Infectious Diseases at John Hopkins University School of Medicine.

Positions